Prolonged survival and time to disease progression with zoledronic acid in patients with bone metastases from non-small cell lung cancer.

Karamanos, Nikos K.; Zarogoulidis, K.; Boutsikou, Efthimia; Zarogoulidis, Pavlos; Kontakiotis, T.

doi:10.1200/jco.2010.28.15_suppl.e18077

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial clinical observations in lung cancer recall issues regarding bone turnover markers discussed by Lipton and colleagues. As one example, patients with non-small cell lung cancer with elevated baseline NTX levels were at greater risk of skeletal related events and death compared to patients with normal NTX levels [15,16].…”

mentioning

confidence: 99%

Emerging role for bisphosphonates in cancer management

Chlebowski

2011

View full text Add to dashboard Cite

Bisphosphonates have become commonly used for preventing and treating osteoporosis [1] and, more recently, to reduce the risk of skeletal related events in cancer patients with bone metastases [2,3]. After initial clinical observations suggested bisphosphonates could favorably influence the course of breast cancer patients with bone metastases [4], both preclinical and clinical studies have aggressively addressed this issue. At present, a series of full-scale randomized clinical trials, planned to involve nearly 25,000 breast cancer patients, are underway to evaluate the role of bisphosphonates and other bone-targeted agents as potential additions to adjuvant therapy management [5]. Most recently, interest in the potential of bisphosphonates to influence breast cancer incidence as a component of primary prevention strategies have emerged as well [5]. In a series of articles in this journal, leaders in this field provide reviews and commentaries on the preclinical science in this area, the current clinical evidence and the definitive information which should emerge in the proximate future regarding the expanding role of bisphosphonates in breast cancer patient management. Doctor's Lipton, Costa, and Coleman present current evidence regarding bone marker use to guide antiresorptive therapy targeting bone [6]. They present data that urinary N-telepeptide of type I collagen (NTX) levels before and during bisphosphonate therapy pro

show abstract

mentioning

confidence: 99%

Emerging role for bisphosphonates in cancer management

Chlebowski

2011

View full text Add to dashboard Cite

show abstract

Bisphosphonates: Prevention of Bone Metastases in Lung Cancer

Decoster¹,

Marinis

Syrigos

et al. 2012

Prevention of Bone Metastases

View full text Add to dashboard Cite

In patients with lung cancer, bone is one of the most frequent sites of distant spread, with approximately 30% of patients developing skeletal metastases. About half of these patients will experience a skeletal-related event, the occurrence of which not only affects quality of life, but is also associated with poor prognosis. Bisphosphonates are currently the mainstay for treating bone metastases in patients with lung cancer, with proven beneficial effects on prevention and delay of skeletal complications. Their role in preventing the development of skeletal metastases, their anti-tumoral properties and their effect on survival remain to be elucidated. Other bone-targeted therapies are being investigated in phase II and III clinical trials and might expand the therapeutic arsenal in the near future.

show abstract